This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
the newly elected Senate majority leader, is big on telehealth, rural hospitals, and increasing transparency for drug middlemen. He represents a state that does not have much in the way of special interests in the health care industry beyond hospitals, doctors, and pharmacists. John Thune (R-S.D.),
But hospitals may be a health care giant they’re unable to confront alone. And after 20 years, they finally delivered on a promise to empower the federal government to lower drugprices in 2022. But the remaining elephant in the room is hospital costs, which make up the biggest share of U.S. health care spending.
Medicare’s new guidelines cover how it will conduct the drugprice negotiations authorized by the Inflation Reduction Act. For example, a new version may make it possible to take a pill instead of an injection or take medicine at home instead of coming to a hospital or infusion center. Read the rest…
EQRx, a company that aimed to lower drugprices by introducing inexpensive me-too medicines, said Tuesday that it has abandoned that plan and is laying off nearly 60% of its workforce. Continue to STAT+ to read the full story…
WASHINGTON — The Senate Finance Committee has drafted a bipartisan bill to mitigate drug shortages by rewarding hospitals for business practices that ensure an adequate supply of drugs. Hospitals band together to negotiate drugprices by hiring group purchasing organizations.
WASHINGTON — Congress will not move forward with a controversial policy to equalize certain Medicare payments to hospitals and physicians’ offices in an upcoming government funding package, five lobbyists and sources following the talks told STAT. The delay is a win for hospitals, which have adamantly lobbied against the policy.
WASHINGTON — Medicare officials are moving forward with a plan to claw back money from certain hospitals to try to remedy overpayments struck down by the Supreme Court, they announced Thursday. Continue to STAT+ to read the full story…
drug discount program overcharged the federal government and numerous hospitals by hundreds of millions of dollars, according to claims made in a recently unsealed lawsuit. There are roughly 12,400 hospitals and clinics that participate across the U.S. and their number has grown over the years.
government agency said that a planned move by Johnson & Johnson to alter payment methods for some hospitals participating in a controversial drug discount program was “inconsistent” with federal law and requires approval before the company can proceed. The statement by the U.S. The move is slated for Oct.
government agency has threatened Johnson & Johnson with sanctions if the company proceeds with plans to alter payment methods for some hospitals that participate in a federal drug discount program. In a letter sent on Tuesday, the U.S. Continue to STAT+ to read the full story…
WASHINGTON — A key House panel on Wednesday advanced several health care bills on Wednesday, including its first step toward a controversial effort to equalize Medicare payments between hospitals and physician offices.
The ins and outs of the new House health package House Republicans on three panels circulated a draft health price transparency package with some reforms to payment practices of PBMs and hospitals, I reported yesterday. Read the rest…
In a victory for the pharmaceutical industry, a federal appeals court ruled drug companies have the right to limit discounts to hospitals that rely on numerous contract pharmacies as they participate in a U.S. government drug discount program.
WASHINGTON — Californians are about to vote on an aggressive policy proposals to reform a drug discount program that is a key source of revenue for hospitals and health clinics. The 340B Drug Discount Program is no exception. The group behind it? Apartment builders.
WASHINGTON — A prominent Senate panel on Wednesday passed a new package of health policy reforms that would rein in certain pharmacy middlemen practices and ensure Medicare patients aren’t paying more than insurers do for medications. The package passed the committee 26-0 with no amendments added. Ron Johnson (R-Wis.)
Belgian anti-trust regulators are probing Roche over concerns that the drug company took steps to delay the entry of biosimilar versions of two of its cancer medicines. The agency also maintained Roche disseminated “erroneous information” about using biosimilars in combination therapy.
American entrepreneur and investor Mark Cuban tells us why he and his partners launched the Mark Cuban Cost Plus Drug Company (MCCPDC), a public-benefit corporation and online pharmacy that provides patients access to medications at a lower cost. . “Manufacturers get a bad rap as being the source of high pricing for patient meds. .”
Over the past week, Areva Pharmaceuticals began marketing vials of fludarabine at a wholesale price of $2,736, much more than the $272 charged for the same dosage by Fresenius Kabi and the $109 price from Teva Pharmaceuticals.
WASHINGTON — House Republicans have drafted drug-shortage legislation that differs significantly from the approach Democrats propose to stem shortages of chemotherapies and other critical medicines that hospitals typically use.
There have been some alarming stories uncovered by the media on ways nonprofit hospitals — many of which participate in the 340B drugpricing program — are taking advantage of the system and their tax-exempt status to boost their bottom lines, at the expense of patients. Here are some recent articles exposing this issue:
Nonprofit hospitals are supposed to help provide access to crucial treatment and services in our most vulnerable communities. But recent research adds to the mountain of evidence showing nonprofit hospitals continue to fall short in their community benefit.
The Federal Trade Commission is launching a probe into the extent to which group purchasing organizations and wholesalers may contribute to ongoing shortages of key medicines at hospitals and other facilities across the country. Three group purchasing organizations, or GPOs, buy drugs on behalf of most hospitals in the U.S.,
WASHINGTON — A nonprofit formed by hospitals to deal with drug shortages is considering a move into chemotherapies. Frustrated by drug shortages and the price spikes that typically ensue, executives from large hospital systems launched the nonprofit Civica Rx to deal with the problem in September 2018.
When rheumatoid arthritis patients enroll in Medicare, switching from private insurance plans, self-administered medications such as Humira and Xeljanz become unaffordable overnight, thanks to the program’s convoluted pricing of at-home prescription drugs. Read the rest…
Meanwhile, employment and salaries in non-retail settings—hospitals, physician offices, outpatient centers, and home healthcare—continued to grow. What’s ahead for 340B-eligible hospitals? Find out during The 340B DrugPricing Program: Trends, Controversies, and Outlook , a new live video webinar with Adam J.
The data mark a steady rise in sales under the 340B Drug Discount Program, which requires drugmakers to offer discounts that are typically estimated to be 25% to 50% — but could be higher — off all outpatient drugs to hospitals and clinics that primarily serve lower-income patients. billion in 2016.
Medicare on a couple of occasions recently has had to deal with billing forms that don’t provide adequate space for prices. Continue to STAT+ to read the full story…
Curl up with your favorite pumpkin-spiced blog and savor these stories harvested from the Drug Channels patch: Fresh insights about hospitals’ specialty drug profits SSR Update: Drugprices keep dropping My $0.02 d/b/a Drug Channels Institute. Autumn is here!
government agency has threatened Johnson & Johnson with sanctions if the company proceeds with plans to alter payment methods for some hospitals that participate in a federal drug discount program , STAT reports. We hope you have a wonderful day, and please do keep in touch. … A U.S.
Drug shortages are particularly vexing because they’re mostly caused by policies within the control of the government, as opposed to outside shocks such as natural disasters.
government agency warned Sanofi that it faces sanctions over plans to change the way payments are made to most hospitals participating in a drug discount program, the third time in recent months that a major pharmaceutical company has been threatened with such a step. The move came after Sanofi disclosed last month that, as of Jan.
Drug middlemen once again were on the hot seat at a congressional hearing on Wednesday. The hearing by the House Education and Workforce health subcommittee was about consolidation in the hospital and health insurance sectors.
I was living on the precipice of end-stage disease when I enrolled in the clinical trial that resulted in the historically fast Food and Drug Administration approval for the game-changing cystic fibrosis drug Trikafta. Five years later, the worst parts of my CF are gone. A decade ago, I would have had a vastly different outcome.
Today, a hospital in Barcelona goes rogue with its own CAR-T treatments, we learn more about Wegovy’s anti-inflammatory mechanisms, and more. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
The common factor behind these two disparate situations: Pharmaceutical wholesalers’ unusual pricing for brand-name drugs sold to pharmacies, hospitals, and other buyers. Below, I walk through the economic fundamentals to help you understand another obscure aspect of our opaque drugpricing system.
A litmus test for states’ drugpricing power Colorado could soon cap how much the state will pay for Amgen’s autoimmune drug Enbrel — in what would be the first such move from a state prescription drug affordability board.
Here’s a summer surprise for fans of the 340B DrugPricing Program: Drug Channels has just obtained the 2021 figures from the Health Resources and Services Administration (HRSA)! Hospitals accounted for 87% of these skyrocketing 340B purchases. The data tell a familiar story. billion —an astonishing $5.9 billion (+$7.0
In a bid to blunt competition and address rising drug costs, Sanofi is offering a warranty that will cover the cost for any hospital if a specific medicine fails to work, marking only the second time a major pharmaceutical company has taken such a step.
health care system to affordable medications,” said Benjamin Rome, one of the study authors and a faculty member at the Program on Regulation, Therapeutics, and Law at Harvard Medical School and Brigham and Women’s Hospital. “The fact that it’s so hard to find savings consistently is disappointing.”
The groups argue that the federal drug discount program has expanded beyond its original mission to help low-income and other vulnerable populations, and instead is benefiting large, well-resourced hospitals. Continue to STAT+ to read the full story…
… House Republicans have drafted drug-shortage legislation that differs significantly from the approach Democrats propose to stem shortages of chemotherapies and other critical medicines that hospitals typically use , STAT explains. Republicans
About last night… House leadership last night canceled a scheduled vote on a health care package that included transparency requirements for hospitals and insurers, reforms to some PBM practices, and a small site-neutral payment policy for administering drugs, Rachel writes. Continue to STAT+ to read the full story…
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content